Phase III
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
The press release has been shrouded with controversy, and the company’s stock fell 16% despite the seemingly optimistic results.
Regeneron and Sanofi’s anti-inflammatory drug Dupixent has shown to be effective against five types of type 2 inflammations, with more indications expected to surface soon.
Recent FDA approval of ViiV Healthcare’s HIV treatment Cabenuva reduced dosing to once every two months.
Anavex Life Sciences announced positive topline results from its Phase III AVATAR trial of Anavex 2-73 (blarcamesione) in adult female patients with Rett syndrome.
Shares of Madrigal Pharmaceuticals went up in premarket trading after the company announced positive topline data from its Phase III assessment of resmetirom in non-alcoholic fatty liver disease.
The FDA’s decision is based on positive results from several Phase III studies, including the TENAYA and LUCERNE clinical trials.
Eli Lilly and Company announced that it was discontinuing the Phase III development program for Olumiant (baricitinib) in lupus.
The resubmission follows a Type B pre-BLA resubmission meeting with the US Food and Drug Administration (FDA).
Clinical trial news definitely picked up this final week of January. Here’s a look.
PRESS RELEASES